Compare TRUP & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRUP | XNCR |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.7M | 881.9M |
| IPO Year | 2014 | 2013 |
| Metric | TRUP | XNCR |
|---|---|---|
| Price | $21.88 | $11.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $45.80 | $22.33 |
| AVG Volume (30 Days) | 351.5K | ★ 608.9K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 295.65 | 65.36 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,439,305,000.00 | $125,576,000.00 |
| Revenue This Year | $11.79 | N/A |
| Revenue Next Year | $8.83 | $4.80 |
| P/E Ratio | $200.00 | ★ N/A |
| Revenue Growth | 11.95 | ★ 13.65 |
| 52 Week Low | $21.16 | $6.92 |
| 52 Week High | $57.35 | $18.69 |
| Indicator | TRUP | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 47.67 |
| Support Level | $21.16 | $10.83 |
| Resistance Level | $29.24 | $12.65 |
| Average True Range (ATR) | 0.94 | 0.53 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 34.80 | 68.29 |
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions. Geographically, the company operates in United States, which derives maximum revenue; and Canada and Others.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.